PetIQ adds MYOS muscle health portfolio with Fortetropin deal

PetIQ is expanding deeper into condition-adjacent pet nutrition with the completed acquisition of MYOS Corp and its Fortetropin-based muscle health portfolio. The move adds a science-forward supplement platform to PetIQ’s pet health business at a time when muscle maintenance, mobility, recovery, and healthy aging are gaining more attention in companion animal care. Trade reports describe the portfolio as clinically studied and built around proprietary, patented Fortetropin technology. (petfoodprocessing.net)

The backdrop here is a pet health market that has steadily pushed beyond basic wellness into targeted, function-specific products. MYOS had already carved out a niche in muscle health, with products aimed at dogs, cats, and horses, plus a veterinary-facing story built around rehabilitation, geriatric mobility, and lean mass preservation. Earlier coverage shows the company had expanded distribution through channels including Chewy, UNFI, and KVP International, suggesting there was already a commercial foundation for broader rollout before this acquisition. (petfoodprocessing.net)

Fortetropin is central to the deal. MYOS describes it as a proprietary fertilized egg yolk-derived ingredient, and company materials say it is backed by multiple patents and more than a dozen studies. The published and company-cited research includes work in dogs recovering from TPLO surgery, older dogs with reduced mobility, cats with chronic kidney disease, and horses. In the TPLO study indexed on PubMed and published in PLOS ONE, dogs receiving Fortetropin showed less loss of thigh circumference and no significant rise in serum myostatin during restricted activity, though the study was manufacturer-funded. MYOS also highlights a Kansas State mobility study in geriatric dogs and feline CKD data pointing to lean mass support without reported adverse renal effects, though some of those findings are summarized in company materials rather than fully detailed in independent publications. (pubmed.ncbi.nlm.nih.gov)

That mix of evidence is likely part of the attraction for PetIQ. In a crowded supplement market, a portfolio with patents, mechanism-based marketing, and at least some peer-reviewed veterinary data stands out. Pet Food Processing previously reported that MYOS received a patent related to Fortetropin’s use in dog muscle loss associated with osteoarthritis, rheumatoid arthritis, and hip dysplasia, bringing its total patent count to eight at the time. That gives PetIQ not just a product line, but intellectual property and a differentiated clinical narrative it can potentially scale across retail and veterinary channels. (petfoodprocessing.net)

I didn’t find substantial independent expert reaction specifically to this acquisition, but the surrounding industry context is clear: pet M&A in 2026 has remained active in targeted health, nutrition, and services categories, with buyers favoring differentiated platforms over undifferentiated commodity products. That makes this transaction look like a strategic tuck-in around a defined need state, not simply line extension. It also fits a broader pattern of investment flowing toward products that can sit between preventive care, chronic management, and quality-of-life support. (petfoodprocessing.net)

Why it matters: For veterinary professionals, the practical question is whether this acquisition changes access, education, and confidence around muscle-support supplementation. It could. If PetIQ expands distribution and clinic-facing support, Fortetropin-based products may become more visible in orthopedic recovery, sports medicine, rehabilitation, senior care, and cases involving cachexia or chronic disease-related muscle loss. At the same time, veterinarians will still need to evaluate where the evidence is strongest, where it remains preliminary, and how to counsel pet parents about realistic outcomes. The portfolio appears more evidence-backed than many nutraceutical competitors, but that doesn’t make every marketing claim equally established. (myosvet.com)

There’s also a workflow implication. Muscle loss is often under-discussed until it becomes obvious, yet it affects recovery timelines, mobility, and long-term function. A more widely distributed product with a recognizable evidence package could make those conversations easier in practice, especially when paired with rehab, weight management, pain control, and disease-specific care plans. For clinics, the opportunity may be less about selling a supplement and more about adding another tool for cases where preserving lean mass is clinically relevant. (myosvet.com)

What to watch: Next, watch for whether PetIQ keeps the MYOS branding, folds Fortetropin into a broader veterinary portfolio, or invests in new independent trials and post-acquisition education. The long-term significance of the deal will depend on whether PetIQ can turn a science-backed but relatively specialized platform into a more standard part of veterinary nutrition and mobility care. (myoscorp.com)